Functional studies performed in cancer with HER2 overexpression have shown that HER2 binds to other receptors of the epidermal growth factor receptor (EGFR) family, thus resulting in dimerisation and phosphorylation of these, even in the absence of ligands [13–14]. The gene discussed is ERBB2; the disease is cancer.